Jefferies lowers Replimune Group stock price target to $8 from $10

Replimune Group (REPL) faces significant uncertainty after receiving a Complete Response Letter (CRL) from the FDA for its RP1 melanoma treatment, contributing to a nearly 59% stock decline over six months. Analyst reactions are mixed: Jefferies maintained a Buy rating despite lowering its price target to $8.00, citing broader FDA leadership turmoil and its potential impact on drug development. Conversely, Cantor Fitzgerald upgraded the stock, while BMO Capital, Barclays, and Leerink Partners downgraded REPL, with BMO and Barclays slashing price targets to $2.00 and $3.00 respectively, reflecting diverse interpretations of the regulatory environment's implications for the company's future prospects.

Analysis

Replimune Group (REPL) is navigating significant turbulence following the FDA's issuance of a Complete Response Letter (CRL) for its melanoma therapy, RP1, which has precipitated a nearly 59% decline in its stock price over the last six months to a current level of $5.29. The regulatory setback, reportedly influenced by a senior FDA official despite initial internal support, has created a sharp divergence in analyst sentiment. Jefferies maintained a Buy rating but lowered its price target to $8.00 from $10.00, attributing the uncertainty to broader turmoil within the FDA's Center for Biologics Evaluation and Research (CBER), including leadership changes which it terms a "double-edge sword." This view is echoed by Cantor Fitzgerald's upgrade to Overweight, which sees potential positives in the FDA leadership shifts. In stark contrast, BMO Capital, Barclays, and Leerink Partners have downgraded the stock, with BMO and Barclays slashing their price targets to $2.00 and $3.00 respectively, reflecting deep pessimism about the company's ability to overcome this unexpected regulatory hurdle. The wide dispersion in price targets, ranging from $2 to $8, underscores the high degree of uncertainty surrounding the company's near-term path to approval for its lead asset.

Key Decisions for Investors

• Investors should recognize the high-risk, event-driven nature of REPL, as the stock's future trajectory is heavily dependent on resolving the FDA's concerns and the subsequent resubmission and review of RP1.
• The significant divergence in analyst price targets, from a low of $2.00 to a high of $8.00, highlights a lack of consensus and indicates that any investment position should be sized according to a high tolerance for volatility and potential binary outcomes.
• Monitor communications from both Replimune and the FDA closely, as any clarification on the path forward for RP1 or stabilization within the CBER's leadership could serve as a major catalyst for the stock.
• Consider the broader regulatory risk for cell and gene therapies, as the turmoil at the FDA noted by analysts may signal systemic challenges that could impact review timelines and approval prospects across the sector, not just for Replimune.